Matthew Keller
Stock Analyst at HC Wainwright & Co.
(0.55)
# 4,496
Out of 5,172 analysts
12
Total ratings
27.27%
Success rate
-21.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.22 | +1,047.54% | 2 | Feb 10, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $6 → $24 | $1.95 | +1,130.77% | 2 | Jan 27, 2026 | |
| IFRX InflaRx | Reiterates: Buy | $6 | $0.94 | +538.30% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $2.75 | +300.00% | 2 | Dec 17, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $31.56 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $5.60 | +453.57% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $6.72 | +167.86% | 1 | Aug 26, 2025 |
Phio Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $14
Current: $1.22
Upside: +1,047.54%
60 Degrees Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $6 → $24
Current: $1.95
Upside: +1,130.77%
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $0.94
Upside: +538.30%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $2.75
Upside: +300.00%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $31.56
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $5.60
Upside: +453.57%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $6.72
Upside: +167.86%